title: How good is a morning cortisol in predicting an adequate response to intramuscular synacthen stimulation?
abstract: BACKGROUND
  Previous studies have demonstrated that a morning serum cortisol of <100 nmol/l makes further dynamic testing such as the Synacthen stimulation test (SST) unnecessary to confirm adrenal insufficiency. The morning cortisol level that reliably predicts adrenal sufficiency (AS) is less well established, and values ranging from 300 to 500 nmol/l have been proposed.
  
  
  OBJECTIVE
  The aim of this study was to determine the ambulatory morning cortisol level that predicts adrenal sufficiency, as defined by an adequate response to SST, using a receiver operating characteristics (ROC) curve.
  
  
  METHODS
  Observational retrospective cross-sectional study.
  We conducted a retrospective audit of SST performed at PathWest Laboratory QEII from January 2006 to August 2008. A total of 761 results were obtained. Patients who were acutely ill or in intensive care, on glucocorticoid therapy, and those with inadequate data or multiple records were excluded from the analysis leaving 505 available for analysis. Baseline serum was obtained prior to intramuscular injection of 250 mcg Synacthen, and a second sample was obtained 30 min post-Synacthen. AS was defined as a 30-min post-Synacthen cortisol of >550 nmol/l; values ≤550 nmol/l were considered inadequate.
  
  
  RESULTS
  Based on SST criteria, of the 505 patients included in the study, 350 patients (69%) were adrenal sufficient and 155 (31%) had adrenal insufficiency. Using the minimum ROC distance criterion, a basal cortisol value of >236 nmol/l was identified to predict AS with sensitivity 84% and specificity 71%. However, to increase the specificity to 95%, we recommend a basal cortisol cut-off of >375 nmol/l. For patients with known pituitary disease (n = 152), basal cortisol of >214 nmol/l (sensitivity 85% and specificity 71%) may obviate the need for SST in the appropriate clinical context, although 330 nmol/l gives a specificity of 95%.
  
  
  CONCLUSIONS
  Basal morning cortisol is a viable first step in the evaluation of patients with suspected adrenal insufficiency.
authors.affiliation: The Alfred Hospital, Melbourne, Vic., Australia.
authors.forename: Wee Shuan
authors.initials: WS
authors.lastname: Yo
authors.forename: Li-Mae
authors.initials: LM
authors.lastname: Toh
authors.forename: Suzanne J
authors.initials: SJ
authors.lastname: Brown
authors.forename: Warwick D
authors.initials: WD
authors.lastname: Howe
authors.forename: David E
authors.initials: DE
authors.lastname: Henley
authors.forename: Ee Mun
authors.initials: EM
authors.lastname: Lim
mesh_terms: D000293:Adolescent; D000309:Adrenal Insufficiency / Q000097:blood / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003366:Cosyntropin / Q000008:administration & dosage* / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010912:Pituitary-Adrenal Function Tests; D012189:Retrospective Studies; D013997:Time Factors; D055815:Young Adult
chemical_list: D003366:Cosyntropin; C006418:adrenocorticotropin zinc; D006854:Hydrocortisone